Ascletis Pharma Statistics
Total Valuation
Ascletis Pharma has a market cap or net worth of 2.29 billion. The enterprise value is 2.03 billion.
| Market Cap | 2.29B |
| Enterprise Value | 2.03B |
Important Dates
The next estimated earnings date is Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.06B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -6.18% |
| Shares Change (QoQ) | -2.46% |
| Owned by Insiders (%) | 56.41% |
| Owned by Institutions (%) | 1.46% |
| Float | 191.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6,926.93 |
| PB Ratio | 8.77 |
| P/TBV Ratio | 8.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -56.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -46.55 |
Financial Position
The company has a current ratio of 14.57, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.57 |
| Quick Ratio | 14.52 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -1,922.65 |
Financial Efficiency
Return on equity (ROE) is -12.77% and return on invested capital (ROIC) is -12.96%.
| Return on Equity (ROE) | -12.77% |
| Return on Assets (ROA) | -12.32% |
| Return on Invested Capital (ROIC) | -12.96% |
| Return on Capital Employed (ROCE) | -22.50% |
| Weighted Average Cost of Capital (WACC) | 7.29% |
| Revenue Per Employee | 1,587 |
| Profits Per Employee | -173,528 |
| Employee Count | 208 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +777.56% in the last 52 weeks. The beta is 0.55, so Ascletis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +777.56% |
| 50-Day Moving Average | 1.41 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 64.07 |
| Average Volume (20 Days) | 4,701 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ascletis Pharma had revenue of 329,992 and -36.09 million in losses. Loss per share was -0.04.
| Revenue | 329,992 |
| Gross Profit | 119,490 |
| Operating Income | -58.78M |
| Pretax Income | -36.09M |
| Net Income | -36.09M |
| EBITDA | -56.98M |
| EBIT | -58.78M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 251.39 million in cash and 595,634 in debt, with a net cash position of 250.80 million.
| Cash & Cash Equivalents | 251.39M |
| Total Debt | 595,634 |
| Net Cash | 250.80M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 260.73M |
| Book Value Per Share | 0.27 |
| Working Capital | 237.00M |
Cash Flow
In the last 12 months, operating cash flow was -43.43 million and capital expenditures -255,870, giving a free cash flow of -43.69 million.
| Operating Cash Flow | -43.43M |
| Capital Expenditures | -255,870 |
| Free Cash Flow | -43.69M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 36.21% |
| Operating Margin | -17,811.19% |
| Pretax Margin | -10,937.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ascletis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.18% |
| Shareholder Yield | 6.18% |
| Earnings Yield | -1.58% |
| FCF Yield | -1.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascletis Pharma has an Altman Z-Score of 15.13 and a Piotroski F-Score of 2.
| Altman Z-Score | 15.13 |
| Piotroski F-Score | 2 |